TScan Therapeutics
TCR discovery company that cut 75% of staff in September 2026 to focus on in vivo-engineered TCR-T for solid tumours (PRAME, MAGE-A4).
Paused the phase 3 ALLOHA-2 trial of TSC-101 for lack of capital; two in vivo TCR-T candidates (PRAME, MAGE-A4) entering IND-enabling studies with phase 1 planned Q4 2027. Previously ran a multiplexed autologous TCR-T basket study in solid tumours.
Pages like this
not linked directly; found by shared links- CompanySana Biotechnology
Shares In vivo CAR-T and the tag pivot.
- IdeaExtending sarcoma TCR-T beyond HLA-A*02
Shares MAGE-A4, TCR-T cell therapy.
- CompanyImmatics
Shares Antibodies that see mutant KRAS and p53 fragments displayed on the cell surface, TCR-T cell therapy.
- Key paperSPEARHEAD-1: afamitresgene autoleucel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma
Shares MAGE-A4, TCR-T cell therapy.
- RoadmapCell therapy roadmap: CD19 CAR-T → solid tumours → in vivo CAR
Shares MAGE-A4, In vivo CAR-T, TCR-T cell therapy.
- ProductAfamitresgene autoleucel
Shares MAGE-A4, TCR-T cell therapy.
- ProductTebentafusp
Shares Antibodies that see mutant KRAS and p53 fragments displayed on the cell surface, TCR-T cell therapy.
- PathwayAntigen presentation & immune editing
Shares MAGE-A4, TCR-T cell therapy.